A recently developed oral small-molecule TPH inhibitor (telotristat ethyl) which acts only on the TPH in the periphery without crossing the blood–brain, thus inevitably inhibiting selectively THP1, was assessed in 2 randomized phase III trials (TELESTAR and TELECAST) in patients with CS. The gene discussed is GLI2; the disease is Cowden syndrome 1.